In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status
{{output}}
Kosiborod MN, Verma S, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of t... ...
